Close menu




October 12th, 2026 | 05:28 CEST

Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!

  • Oncology
  • Cancer Therapy
  • Pharma
  • Biotechnology
  • Clinical Trials
  • Innovation
Photo credits: Pixabay

New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: Vidac Pharma Holding PLC | GB00BM9XQ619 , BAYER AG NA | DE000BAY0017 , EVOTEC SE INH | DE0005664809

Vidac Pharma: Green Light for Its European Offensive

Vidac is pursuing a novel approach in cancer medicine. The company's active substances are intended to influence the disrupted energy metabolism of cancer cells, thereby inhibiting their growth and ultimately promoting cell death. The focus is on the interaction between the proteins HK2 and VDAC. The most promising clinical candidate is VDA-1102, an ointment for treating actinic keratosis, a sun-induced skin condition with a potential cancer risk.

In the short term, attention is focused on the results of VDA-1102's Phase 2b trial in actinic keratosis. Following the completion of patient follow-up in September 2026, Vidac announced a final data analysis. Positive results could pave the way for further clinical development and attract the interest of potential partners. Progress in other indications and new trial data could provide additional impetus. In its September 14 announcement, Vidac presented the final data review and statistical analysis. Results, including tissue analyses, were expected in the following weeks.

Other development programmes concern cutaneous T-cell lymphoma and solid tumours. With VDA-1275, Vidac is also working on a preclinical drug candidate intended to alter cancer metabolism and potentially enhance the effect of established chemotherapies.

The latest annual general meeting resolutions expand Vidac's financing flexibility and allow the issuance of further shares. Shareholders also approved the planned collaboration with the French company Eutopos Pharma, which is intended to raise capital, coordinate clinical development and advance strategic partnerships from Strasbourg. In addition, management is financing growth by selling shares and making the proceeds available to the company as fresh capital.

Bayer: Mixed Picture

The life sciences group operates in two areas, each accounting for almost half of revenue, which analysts estimate at EUR 45.9 billion in the current financial year. Crop Science, which offers solutions for agriculture and crop protection, remains the problem child because of the glyphosate litigation since the Monsanto acquisition in 2018. Plaintiffs allege that the group's weedkiller Roundup causes cancer. After a favourable US Supreme Court ruling for Bayer in the summer, the German company continues to seek a class action settlement of up to USD 7.25 billion, though final court approval following the September 14 hearing is still pending. A firm completion date is not yet foreseeable.

The Pharmaceuticals division develops prescription medicines, for example for cancer and cardiovascular diseases. Consumer Health, by contrast, offers over-the-counter healthcare products. These two segments account for the other half of total revenue. In the second quarter, Bayer generated group revenue of EUR 10.9 billion and adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) of EUR 2.1 billion. The bottom line was a profit of EUR 219 million. Net debt stood at EUR 33.6 billion at the reporting date. According to the company, this is to be reduced to EUR 29 to 30 billion by the end of the year.

Bayer's pharmaceuticals business reflects the typical life cycle of medicines. While the prostate cancer drug Nubeqa grew 64% in the second quarter on a currency- and portfolio-adjusted basis, the blockbusters Xarelto (anticoagulant) and Eylea (eye medicine) are coming under pressure from expiring patent protection and competing products. New medicines are intended to offset the revenue losses. Alongside Nubeqa, the group sees considerable potential in Kerendia for treating certain kidney and cardiovascular diseases.

To strengthen its balance sheet, Bayer agreed in July to a hybrid capital injection of EUR 3 billion for its long-acting contraceptives business, which includes hormonal intrauterine devices, with financial investor Apollo. The transaction was completed in mid-September, with KKR participating as an additional investor. This allows Bayer to strengthen its balance sheet with equity-like funds without raising capital.

Successes have also been reported elsewhere recently. In September, the US Food and Drug Administration (FDA) granted accelerated approval for sevabertinib as a first-line treatment for adults with advanced or metastatic non-small cell lung cancer (NSCLC) and certain HER2 mutations. Bayer is thereby expanding the cancer medicine's scope of use and the potential patient and revenue base. The German company will publish its third-quarter figures on November 3. On average, analysts see just over 30% upside potential for the stock.

Evotec: In Principle, but…

In principle, there are several positive factors that could boost the biotech sector, but they do not apply to every company. Amid the AI boom, investors are increasingly looking at companies in the sector. Market participants are betting that artificial intelligence will accelerate the development of new medicines and, in turn, boost demand for laboratory equipment, research technology and testing systems. Recently, individual M&A transactions have also provided grounds for optimism.

With the annual forecast lowered in the summer to revenue of EUR 570 to 610 million and a higher adjusted EBITDA loss of between EUR 70 and 105 million, investors once again had to absorb a blow. The company cited deferred contributions from existing partnerships and lower expected revenue from new collaborations as the reasons. Management expects improved new business to have a greater impact on revenue from the fourth quarter onwards. A few weeks ago, optimistic statements from CFO Claire Hinshelwood on business indicators, the progress of the savings programme "Horizon" and the pipeline enthused investors. Perhaps the Q3 figures on November 5 and upcoming conferences will soon provide better visibility.

As of today, the shares were trading at around EUR 2.80, giving the company a market capitalisation of just EUR 500 million. In the first half of 2026, revenue fell 19% to EUR 300 million. Adjusted EBITDA was minus EUR 42.7 million, and net loss was EUR 168.6 million. Operating cash outflow reached EUR 111 million. Analysts set an average price target of EUR 4.60.

Conclusion

Vidac Pharma is at an important juncture. New positive trial data could soon boost the shares. Bayer and Evotec will each publish their next quarterly figures in early November. Bayer needs more clarity on the legal dispute, while Evotec must increase orders and reduce costs.


Conflict of interest

Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

For this reason, there is a concrete conflict of interest.

The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

Risk notice

Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


Der Autor

Carsten Mainitz

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author



Related comments:

Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

  • Biotechnology

Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

Read

Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

  • Evotec
  • Vidac Pharma
  • Novo Nordisk
  • Drug discovery
  • Biotech
  • Pharma
  • Cancer
  • Oncology
  • Warburg effect
  • Obesity
  • Diabetes
  • Weight-loss pill

Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

Read

Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

  • Bayer
  • Cardiol Therapeutics
  • Novartis
  • Heart disease
  • Asundexian
  • Pharma
  • Pericarditis
  • CardiolRx
  • Leqvio

Created and Published on Behalf of Cardiol Therapeutics

Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

Read